Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and XXXX .

@entity1 @entity1007 @entity1674 @entity2101 @entity165
Low density lipoprotein (LDL) apheresis is an effective treatment option for @entity1 with severe @entity1007 not adequately responding to diet and drug therapy. Membrane differential filtration (MDF), synonymous with double filtration plasmapheresis (DFPP), here named Lipidfiltration, and @entity2101 ( @entity2101 ) are two of the five methods available for extracorporeal LDL apheresis. In this prospective investigation 6 @entity1 with severe LDL- @entity1007 and CAD were treated in a cross-over design with Lipidfiltration at two stages of technical development and @entity2101 to compare the efficacy of these two LDL apheresis methods with respect to lowering and modifying plasma lipids and rheologically relevant plasma proteins, especially fibrinogen. In total, 44 LDL apheresis sessions were investigated. In weekly intervals, @entity1 were treated with consecutive LDL apheresis sessions with either Lipidfiltration and @entity2101 , treating identical plasma volumes. In one part of the investigation Lipidfiltration was performed with the novel Lipidfilter EC-50, combined with a newly developed blood and plasma therapy machine allowing optimized plasma heating. The results showed that the reduction rates of LDL- @entity165 , lipoprotein(a) and @entity1674 were essentially identical for both methods. Also pretreatment levels of total @entity165 , @entity1674 , LDL- @entity165 and HDL- @entity165 were not significantly different in both treatment groups. Both methods lead to a significant reduction of serum lipoproteins, especially for LDL- @entity165 , which was decreased by 61.4% with Lipidfiltration (treated plasma volume: 2998 ml) and 61.3% with @entity2101 (treated plasma volume: 3013 ml). With respect to Lipidfiltration LDL- @entity165 reduction was more efficient with the novel Lipidfilter EC-50. Mean pretreatment HDL @entity165 concentrations remained unchanged. Comparing Cascadeflo AC-1770 with the novel Lipidfilter EC-50 reduction rates of HDL- @entity165 (17.4% versus 6.4%) and total protein (17.9% versus 7.8%) were significantly reduced. Lipidfiltration and @entity2101 both resulted in a reduction of plasma viscosity and hemorheologically relevant plasma proteins, like fibrinogen.
